A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

Bethesda, MD - A new single-center report of 100 cases of percutaneous closure of patent foramen ovales (PFOs) and atrial-septal defects (ASDs) shows excellent results in terms of defect closure, with ...

Overall, there was a 15.8% incidence of migraines in the first 3 months following the procedure among people randomized to clopidogrel (Plavix) plus aspirin or aspirin alone. After this initial period ...

Long-term survival after transcatheter closure of secundum atrial septal defects (ASD) is similar to that achieved after surgical closure, but the former method is far more likely to require ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio W.L. Gore and Associates announced its ...

While rare, infective endocarditis is a devastating complication after device closure of atrial septal defects (ASDs), and much remains unknown about when infections begin and how clinicians can best ...

LOS ANGELES, CA--(Marketwired - March 10, 2016) - Dr. Niels Erik Nielsen, Director of Structural Heart Interventions at the Linkoping University Hospital in Linkoping Sweden, successfully performed ...

A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect ...